ValuEngine downgraded shares of Cerus (NASDAQ:CERS) from a strong-buy rating to a buy rating in a research report report published on Monday.

Several other research firms have also recently commented on CERS. BidaskClub raised shares of Cerus from a hold rating to a buy rating in a research note on Wednesday, August 29th. Cantor Fitzgerald reissued a buy rating and set a $9.00 target price on shares of Cerus in a research note on Wednesday, October 3rd. Zacks Investment Research cut shares of Cerus from a buy rating to a hold rating in a research note on Friday, October 5th. Finally, Cowen set a $10.00 target price on shares of Cerus and gave the company a buy rating in a research note on Friday, August 3rd. One analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company. The stock currently has a consensus rating of Hold and an average price target of $8.00.

Shares of NASDAQ:CERS traded up $0.06 on Monday, reaching $5.11. 52,425 shares of the company’s stock were exchanged, compared to its average volume of 1,105,545. The company has a debt-to-equity ratio of 0.26, a quick ratio of 3.17 and a current ratio of 3.48. Cerus has a fifty-two week low of $3.35 and a fifty-two week high of $8.05. The stock has a market capitalization of $715.08 million, a price-to-earnings ratio of -8.96 and a beta of 1.54.

Cerus (NASDAQ:CERS) last released its earnings results on Thursday, November 1st. The biotechnology company reported ($0.11) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.11). The firm had revenue of $15.40 million for the quarter, compared to analysts’ expectations of $15.40 million. Cerus had a negative net margin of 74.95% and a negative return on equity of 68.90%. Cerus’s quarterly revenue was up 42.6% on a year-over-year basis. During the same quarter last year, the company earned ($0.12) EPS. Sell-side analysts expect that Cerus will post -0.43 EPS for the current fiscal year.

In related news, CFO Kevin Dennis Green sold 50,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 28th. The shares were sold at an average price of $7.50, for a total transaction of $375,000.00. Following the completion of the sale, the chief financial officer now directly owns 110,825 shares in the company, valued at $831,187.50. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Over the last 90 days, insiders have sold 58,349 shares of company stock valued at $427,571. 6.80% of the stock is currently owned by corporate insiders.

Institutional investors and hedge funds have recently modified their holdings of the stock. Jane Street Group LLC bought a new position in Cerus during the first quarter valued at approximately $107,000. First Quadrant L P CA acquired a new stake in shares of Cerus in the third quarter worth $112,000. Advisory Services Network LLC bought a new stake in shares of Cerus in the 2nd quarter valued at about $130,000. Paloma Partners Management Co acquired a new position in shares of Cerus in the 2nd quarter valued at approximately $150,000. Finally, Xact Kapitalforvaltning AB acquired a new position in shares of Cerus in the 2nd quarter valued at approximately $183,000. 58.69% of the stock is currently owned by hedge funds and other institutional investors.

Cerus Company Profile

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System is based on its proprietary technology for controlling biological replication; and targets and inactivates blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products.

Further Reading: What is a capital gain?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.